

Consumer Healthcare turnover

Three months ended 30 September 2014

	Total		
	£m	CER%	AR%
Turnover			
Wellness	394	(8)	(15)
Oral health	446	2	(6)
Nutrition	160	4	-
Skin health	71	(13)	(21)
Total	1,071	(3)	(10)

	Total		
	£m	CER%	AR%
Turnover			
USA	202	(7)	(13)
Europe	310	(5)	(12)
ROW	559	1	(7)
Total	1,071	(3)	(10)

Consumer Healthcare turnover

Nine months ended 30 September 2014

	Total		
	£m	CER%	AR%
Turnover			
Wellness	1,176	(8)	(17)
Oral health	1,337	2	(7)
Nutrition	481	8	(3)
Skin health	226	(12)	(20)
Total	3,220	(2)	(11)

	Total		
	£m	CER%	AR%
Turnover			
USA	599	(9)	(16)
Europe	929	(7)	(12)
ROW	1,692	3	(10)
Total	3,220	(2)	(11)

Pharmaceuticals and Vaccines turnover – Three months ended 30 September 2014

	Total			USA			Europe			Emerging Markets			Japan		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	1,404	(8)	(14)	624	(18)	(24)	387	(3)	(7)	186	13	2	97	3	(8)
<i>Avamys/Veramyst</i>	52	2	(5)	8	(31)	(38)	13	15	-	18	5	(10)	7	60	40
<i>Flixotide/Flovent</i>	148	(6)	(14)	90	(8)	(14)	21	(12)	(16)	14	25	17	7	(22)	(22)
<i>Relvar/Breo</i>	15	-	-	8	-	-	4	-	-	-	-	-	2	-	-
<i>Seretide/Advair</i>	976	(13)	(19)	441	(25)	(30)	314	(5)	(9)	94	20	8	54	(5)	(13)
<i>Ventolin</i>	156	16	8	76	26	15	28	-	(3)	40	10	3	2	-	-
Other	57	2	(3)	1	-	-	7	-	-	20	(8)	(17)	25	7	(7)
Oncology	311	35	25	132	44	33	110	26	21	42	33	17	17	19	6
<i>Arzerra</i>	14	(17)	(22)	5	(54)	(62)	7	100	75	-	-	-	1	-	-
<i>Mekinist</i>	18	>100	>100	18	>100	>100	-	-	-	-	-	-	-	-	-
<i>Promacta</i>	62	37	27	25	42	32	19	33	27	8	50	33	9	25	13
<i>Tafinlar</i>	37	>100	>100	15	>100	>100	20	-	-	-	-	-	-	-	-
<i>Tyverb/Tykerb</i>	42	(15)	(21)	12	(14)	(14)	17	(14)	(19)	11	-	(8)	2	(50)	(50)
<i>Votrient</i>	107	27	18	48	44	33	38	5	(3)	12	40	20	5	100	67
Other	31	10	-	9	10	(10)	9	(42)	(25)	11	63	38	-	-	-
Cardiovascular, metabolic and urology (CVMU)	231	(5)	(12)	83	(18)	(25)	71	(1)	(7)	35	15	6	28	14	-
<i>Avodart</i>	195	2	(6)	58	(15)	(21)	70	10	4	27	12	4	28	14	-
Other	36	(33)	(35)	25	(24)	(32)	1	(89)	(89)	8	29	14	-	-	-
Immuno-inflammation	65	46	35	60	44	33	3	50	50	1	-	-	-	-	-
<i>Benlysta</i>	45	14	7	40	10	3	3	50	50	1	-	-	-	-	-
Other	20	>100	>100	20	>100	>100	-	-	-	-	-	-	-	-	-
Other pharmaceuticals	545	(8)	(16)	35	(55)	(55)	142	(20)	(25)	261	8	(2)	49	(2)	(11)
<i>Dermatology</i>	109	(30)	(34)	12	(68)	(70)	30	(24)	(29)	57	(11)	(19)	5	-	(17)
<i>Augmentin</i>	137	6	(2)	1	-	-	42	5	(2)	88	7	(2)	3	-	-
Other anti-bacterials	45	4	(2)	1	(50)	(50)	11	(8)	(15)	31	6	(3)	(1)	(100)	<(100)
Rare diseases	103	(10)	(18)	15	(47)	(50)	34	13	6	11	(8)	(15)	39	(2)	(13)
Other	151	-	(12)	6	(20)	20	25	(54)	(58)	74	38	21	3	-	-
Innovative Pharmaceuticals	2,556	(3)	(10)	934	(12)	(19)	713	(3)	(8)	525	12	1	191	4	(6)
Vaccines	922	-	(7)	337	(3)	(10)	259	-	(5)	274	13	4	7	50	17
<i>Boostrix</i>	106	37	28	61	18	9	23	28	28	18	>100	>100	-	-	-
<i>Cervarix</i>	31	(17)	(24)	2	-	-	11	(14)	(21)	17	(24)	(32)	-	-	-
<i>Fluarix, FluLaval</i>	122	(8)	(14)	94	(3)	(10)	16	6	-	12	86	71	-	-	-
Hepatitis	148	(6)	(12)	67	(10)	(17)	46	6	(4)	24	(10)	(17)	-	-	-
<i>Infanrix, Pediarix</i>	212	(12)	(18)	84	(10)	(16)	87	(5)	(11)	27	(32)	(39)	-	-	-
<i>Rotarix</i>	102	2	(6)	27	(9)	(16)	17	6	-	47	2	(6)	7	50	17
<i>Synflorix</i>	101	34	26	-	-	-	13	17	8	88	41	33	-	-	-
Other	100	-	(7)	2	-	-	46	(8)	(8)	41	16	8	-	-	-
Innovative Pharmaceuticals and Vaccines	3,478	(2)	(9)	1,271	(10)	(16)	972	(2)	(7)	799	12	2	198	6	(6)
ViiV Healthcare (HIV)	373	18	8	166	32	22	130	12	6	38	(13)	(25)	17	48	31
<i>Combivir</i>	12	(48)	(52)	2	(62)	(64)	4	(45)	(48)	4	(41)	(46)	1	(3)	(14)
<i>Epzicom/Kivexa</i>	198	13	4	71	18	10	82	9	3	23	13	(4)	9	13	-
<i>Lexiva/Agenerase</i>	21	(21)	(28)	11	(23)	(29)	5	(26)	(30)	5	(10)	(23)	-	-	-
<i>Selzentry</i>	30	(6)	(12)	12	(13)	(19)	14	1	(4)	2	27	2	1	(14)	(23)
<i>Tivicay</i>	78	>100	>100	53	>100	>100	16	-	-	-	-	-	5	-	-
<i>Trizivir</i>	9	(58)	(63)	3	(78)	(79)	6	(22)	(26)	-	-	-	-	-	-
Other	25	(24)	(34)	14	(16)	(25)	3	(53)	(42)	4	(40)	(60)	1	100	-
Established products	724	(14)	(20)	187	(37)	(42)	139	(15)	(19)	273	21	11	107	(19)	(28)
<i>Coreg</i>	26	(19)	(28)	27	(22)	(25)	-	-	-	-	-	-	-	-	-
<i>Hepsera</i>	19	40	27	-	-	-	-	-	-	14	50	40	5	-	(17)
<i>Imigran/Imitrex</i>	38	(15)	(19)	15	(24)	(29)	16	13	7	2	100	100	4	(33)	(33)
<i>Lamictal</i>	132	3	(5)	64	(1)	(9)	25	4	(7)	19	11	-	22	14	5
<i>Lovaza</i>	53	(58)	(61)	53	(57)	(60)	-	-	-	-	-	-	-	-	-
<i>Requip</i>	27	(19)	(25)	1	(67)	(67)	10	(15)	(23)	3	(25)	(25)	12	(13)	(20)
<i>Serevent</i>	27	(9)	(16)	12	(8)	(8)	11	(8)	(15)	-	-	-	2	-	(33)
<i>Seroxat/Paxil</i>	51	(11)	(20)	-	-	-	9	(25)	(25)	17	25	6	24	(24)	(29)
<i>Valtrex</i>	36	(29)	(35)	5	(50)	(50)	6	(25)	(25)	9	(9)	(18)	12	(50)	(54)
<i>Zeffix</i>	42	70	56	-	-	-	2	(33)	(33)	37	>100	>100	3	(25)	(25)
Other	273	(8)	(15)	10	(60)	(67)	60	(23)	(26)	172	11	3	23	(15)	(32)
	4,575	(3)	(10)												

The table above includes the sales by product reported in Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccines tender sales and contract manufacturing sales) in the total column only. US dollar amounts shown above are a convenience translation of the sterling amounts.

Pharmaceuticals and Vaccines turnover – Nine months ended 30 September 2014

	Total			USA			Europe			Emerging Markets			Japan		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	4,517	(9)	(16)	2,028	(17)	(23)	1,266	(3)	(6)	560	4	(8)	340	(2)	(15)
<i>Avamys/Veramyst</i>	180	2	(8)	23	(31)	(36)	54	8	2	53	15	-	37	8	(8)
<i>Flixotide/Flovent</i>	513	(5)	(13)	319	(4)	(11)	75	(10)	(14)	39	10	(5)	21	(20)	(30)
<i>Relvar/Breo</i>	29	-	-	14	-	-	9	-	-	1	-	-	5	-	-
<i>Seretide/Advair</i>	3,110	(14)	(20)	1,424	(24)	(30)	1,014	(4)	(7)	289	5	(7)	166	(2)	(15)
<i>Ventolin</i>	484	13	4	241	23	14	90	(1)	(4)	118	8	(5)	5	-	(17)
Other	201	(7)	(17)	7	100	>100	24	-	-	60	(18)	(27)	106	(6)	(19)
Oncology	867	34	23	359	39	29	311	29	24	122	39	18	46	13	(2)
<i>Arzerra</i>	42	(20)	(25)	22	(27)	(33)	17	(18)	(23)	-	-	-	2	100	100
<i>Mekinist</i>	47	>100	>100	46	>100	>100	-	-	-	-	-	-	-	-	-
<i>Promacta</i>	165	34	23	64	28	19	53	41	36	20	44	25	24	27	9
<i>Tafinlar</i>	92	>100	>100	40	>100	>100	46	-	-	-	-	-	-	-	-
<i>Tyverb/Tykerb</i>	129	(11)	(18)	33	(20)	(25)	53	(13)	(16)	34	18	3	6	(46)	(54)
<i>Votrient</i>	295	33	22	127	30	21	114	25	20	33	54	27	11	86	57
Other	97	-	(8)	27	(15)	(21)	28	(10)	(10)	35	46	25	3	(25)	(25)
Cardiovascular, metabolic and urology (CVMU)	705	(3)	(11)	256	(19)	(25)	223	2	(2)	103	18	4	81	16	-
<i>Avodart</i>	593	2	(6)	184	(15)	(21)	211	9	5	80	18	4	81	16	-
Other	112	(24)	(30)	72	(28)	(33)	12	(54)	(54)	23	18	5	-	-	-
Immuno-inflammation	153	43	33	140	41	31	9	50	50	2	100	100	-	-	-
<i>Benlysta</i>	124	23	14	111	19	10	9	50	50	2	100	100	-	-	-
Other	29	>100	>100	29	>100	>100	-	-	-	-	-	-	-	-	-
Other pharmaceuticals	1,742	-	(9)	110	(44)	(47)	468	(6)	(10)	778	5	(7)	182	15	(1)
Dermatology	358	(21)	(28)	36	(63)	(65)	114	(8)	(11)	177	(10)	(20)	17	(5)	(19)
<i>Augmentin</i>	436	2	(6)	1	-	-	143	(1)	(5)	271	3	(7)	8	-	(11)
Other anti-bacterials	156	1	(7)	4	(20)	(20)	45	(2)	(6)	104	3	(7)	1	-	(50)
Rare diseases	308	(7)	(16)	48	(41)	(44)	101	11	6	31	3	(9)	114	(2)	(16)
Other	484	29	14	21	69	62	65	(29)	(35)	195	30	9	42	>100	>100
Innovative Pharmaceuticals	7,984	(2)	(10)	2,893	(13)	(19)	2,277	-	(3)	1,565	8	(5)	649	5	(9)
Vaccines	2,346	3	(4)	701	3	(5)	738	(1)	(5)	747	11	2	21	(11)	(25)
<i>Boostrix</i>	260	42	32	134	22	14	64	32	28	46	>100	>100	-	-	-
<i>Cervarix</i>	87	(24)	(31)	4	(20)	(20)	36	(10)	(14)	46	(21)	(31)	-	-	-
<i>Fluarix, FluLaval</i>	137	(10)	(16)	96	(6)	(13)	15	14	7	22	19	5	-	-	-
Hepatitis	410	(8)	(14)	167	(13)	(20)	139	-	(5)	73	(9)	(18)	-	-	-
<i>Infanrix, Pediarix</i>	616	1	(6)	221	13	5	272	(4)	(8)	81	(9)	(19)	-	-	-
<i>Rotarix</i>	291	15	6	77	(1)	(8)	50	18	14	132	24	12	21	47	24
<i>Synflorix</i>	268	16	10	-	-	-	34	-	(6)	231	20	14	-	-	-
Other	277	(6)	(12)	2	-	-	128	(10)	(12)	116	1	(6)	-	-	-
Innovative Pharmaceuticals and Vaccines	10,330	(1)	(9)	3,594	(10)	(16)	3,015	-	(4)	2,312	9	(3)	670	5	(10)
ViiV Healthcare (HIV)	1,036	12	3	439	24	15	386	3	(1)	102	(8)	(22)	43	28	10
<i>Combivir</i>	44	(44)	(48)	8	(63)	(65)	15	(52)	(54)	18	(17)	(25)	2	(9)	(22)
<i>Epzicom/Kivexa</i>	563	10	2	197	12	4	249	8	4	53	5	(12)	26	14	(2)
<i>Lexiva/Agenerase</i>	64	(18)	(25)	33	(20)	(25)	16	(24)	(27)	12	-	(17)	1	(20)	(31)
<i>Selzentry</i>	101	1	(5)	38	(6)	(13)	45	1	(3)	5	14	(5)	2	(12)	(25)
<i>Tivicay</i>	173	>100	>100	127	>100	>100	32	-	-	-	-	-	8	-	-
<i>Trizivir</i>	27	(59)	(62)	7	(82)	(83)	18	(26)	(28)	1	(50)	(60)	-	-	-
Other	64	(28)	(35)	29	(5)	(12)	11	(49)	(61)	13	(42)	(46)	4	(29)	(43)
Established products	2,234	(17)	(24)	626	(31)	(36)	457	(13)	(16)	780	(2)	(12)	329	(14)	(26)
<i>Coreg</i>	88	(7)	(14)	88	(7)	(13)	-	-	-	-	-	-	-	-	-
<i>Hepsera</i>	63	(5)	(14)	-	-	-	-	-	-	47	(7)	(15)	15	(5)	(21)
<i>Imigran/Imitrex</i>	128	(5)	(10)	61	2	(2)	46	-	(4)	5	-	-	12	(22)	(33)
<i>Lamictal</i>	382	3	(6)	180	(3)	(10)	79	1	(4)	55	7	(5)	62	20	3
<i>Lovaza</i>	185	(55)	(58)	184	(55)	(58)	-	-	-	-	-	-	-	-	-
<i>Requip</i>	81	(7)	(16)	5	-	(17)	32	(20)	(22)	10	-	(9)	34	5	(8)
<i>Serevent</i>	80	(12)	(18)	30	(16)	(21)	37	(5)	(10)	2	(33)	(33)	7	(20)	(30)
<i>Seroxat/Paxil</i>	155	(19)	(28)	-	-	-	31	(22)	(24)	47	(12)	(22)	73	(18)	(29)
<i>Valtrex</i>	110	(25)	(33)	19	(30)	(37)	21	(5)	(5)	25	(3)	(17)	38	(45)	(53)
<i>Zeffix</i>	127	(1)	(9)	2	(70)	(80)	6	(22)	(33)	108	9	1	9	(8)	(25)
Other	835	(13)	(20)	57	(33)	(37)	205	(18)	(21)	481	(3)	(13)	79	(13)	(25)
	13,600	(3)	(11)												

The table above includes the sales by product reported in Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccines tender sales and contract manufacturing sales) in the total column only. US dollar amounts shown above are a convenience translation of the sterling amounts.